• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solventum Launches All-In-One, Extended-Wear Wound Dressing for V.A.C.® Therapy

    9/10/24 6:45:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email

    New V.A.C.® Peel and Place Dressing makes negative pressure wound therapy more accessible, less painful

    ST. PAUL, Minn., Sept. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the launch of the V.A.C.® Peel and Place Dressing, an integrated dressing and drape that can be applied in less than two minutesi and worn by patients for up to seven daysii.

    V.A.C.® Peel and Place Dressing

    Traditional dressings for negative pressure wound therapy typically take more than twice as long to apply, require a multi-step process of measuring and cutting separate foam and adhesive components, and may need to be changed three or more times a week.

    The new V.A.C.® Peel and Place Dressing is the next evolution in V.A.C.® Therapy. It has an all-in-one dressing and drape design that simplifies application and reduces the time and training required for dressing application and changes. It also features a built-in perforated, non-adherent layer that reduces tissue ingrowth and makes dressing removal less painful.

    "I'm impressed with how intuitive the V.A.C.® Peel and Place Dressing is to apply. My colleagues and staff can learn how to use the dressing without extensive or prolonged training," said Dr. Ralph J. Napolitano, Jr, DPM, CWSP, FACFAS, director of Wound Care and Healing at OrthoNeuro in Columbus, OH. "This product is an important innovation in wound care that has the potential to improve outcomes, save both time and money, and enhance the overall patient and clinician experience."

    The V.A.C.® Peel and Place Dressing is indicated for wounds as deep as 6cm including chronic, acute, traumatic, subacute, and dehisced wounds, as well as partial thickness burns, ulcers (such as diabetic, pressure or venous insufficiency), flaps, and grafts. Shown to reduce therapy application time by 61 percenti, the V.A.C.® Peel and Place Dressing can also reduce costs by 41 percent at the hospital bedside due to less frequent dressing changesiii and reduce the number of home nursing visits by 67 percent per weekiv*. 

    "Being able to quickly and safely apply the dressing to deeper and more varied types of wounds, and for it to stay in place for a longer period of time means a reduction in dressing changes, home care visits, and trips to the clinic," said Dot Weir, RN, CWON, CWS, a practicing wound and ostomy care nurse with over four decades of experience. "Because wound care often extends beyond a hospital stay, making the treatment less burdensome and less painful allows patients to get back to their lives more quickly and enables clinicians to ensure consistency of care throughout the healing journey."

    V.A.C.® Therapy is associated with significantly shorter wound healing time.v It has been used worldwide for almost three decades to treat more than 10 million wounds, which are on the rise, largely driven by aging populations and the increased prevalence of chronic conditions like diabetes and obesity.vi The V.A.C.® Peel and Place Dressing enables V.A.C.® Therapy to be used on a wider range of patients across the continuum of care in both acute and post-acute settings.

    "Solventum is committed to overcoming clinical challenges and improving access to care so that more patients may benefit from V.A.C.® Therapy, one of the most studied and effective advanced wound treatments available today," said Chris Barry, executive vice president and group president, Medical Surgical, Solventum. "We are proud to be a pioneering leader in wound care, and we will continue our legacy of innovation by empowering and equipping healthcare providers with the tools they need to deliver better, smarter, and safer treatments to their patients."

    Previewed in 2023 at the Symposium on Advanced Wound Care, the V.A.C.® Peel and Place Dressing is available now in the United States and Canada. Additional global regulatory submissions and approvals are pending.

    About Solventum

    At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

    Disclosures

    Dr. Napolitano is a consultant and speaker for Solventum and Engineered Tissue Solutions. He is also a speaker for Ortho Dermatologics.

    Dot Weir is a consultant and speaker for Solventum.

    i In a simulated use test with 12 nurse and surgeon users. 3M™ V.A.C.® Peel and Place Dressing took on average, 01:48 to apply whereas 3M™ traditional NPWT foam dressing and hybrid acrylic-silicone drape took on average, 04:40 to apply (p<0.01, Wilcoxon signed rank test). SAT-MTF-05-995965 Marketing study for 3M V.A.C. Peel and Place dressing. 2023.

    ii SAT-BSER-05-869347 VAC Peel and Place (Ganymede) BSER. 510(k) K222859.

    iii Cost associated with dressing application labor and dressing product cost, based on 2024 average product prices, 2024 US RN pay rates, and a 3 to 1 dressing change weekly frequency. CLIN-SUPPORT-05-1022946 2024 Health Economic Data and Calculator for V.A.C. Peel and Place Claim. 2024.

    iv 510(k) K222859 [V.A.C. Peel and Place dressing]; SAT-TEST-RPT-05-893424 Ganymede FDA System Test 2022 [V.A.C. Peel and Place dressing]; SAT-TEST-RPT-05-794416 FDA System Functional Test Report [V.A.C./Dermatac/Granufoam system] 72 hr performance test. 2022.

    *Based on 3M™ V.A.C.® Peel and Place Dressing up to 7 day wear time and the 3M™ V.A.C.® Granufoam™ Dressing recommendation of dressing changes every 2-3 days

    v Chowdhry SA, Wilhelmi BJ. Comparing Negative Pressure Wound Therapy with Instillation and Conventional Dressings for Sternal Wound Reconstructions. Plastic and Reconstructive Surgery Global Open. 2019 Jan 4;7(1):e2087.

    vi KCI, Cumulative NPWT Wounds. 2021.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-launches-all-in-one-extended-wear-wound-dressing-for-vac-therapy-302242516.html

    SOURCE Solventum

    Get the next $SOLV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    1/26/2026$97.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/20/2026$100.00Neutral → Outperform
    Mizuho
    12/2/2025$100.00Neutral → Buy
    BTIG Research
    10/1/2025$77.00Neutral
    UBS
    9/11/2025$80.00Hold
    Jefferies
    7/15/2025$103.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$90.00Hold → Buy
    Argus
    6/6/2025Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Feb. 26, 2026 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 Internation

    2/3/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Completes Acquisition of Acera Surgical

    Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac

    12/23/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

    New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™  Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology ST. PAUL, Minn., Dec. 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the consensus recommendations of an international, multidisciplinary panel of surgeons and wound care experts on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dr

    12/17/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Solventum upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Solventum from Sector Weight to Overweight and set a new price target of $97.00

    1/26/26 8:32:07 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by Mizuho with a new price target

    Mizuho upgraded Solventum from Neutral to Outperform and set a new price target of $100.00

    1/20/26 8:47:32 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by BTIG Research with a new price target

    BTIG Research upgraded Solventum from Neutral to Buy and set a new price target of $100.00

    12/2/25 8:17:55 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Landucci Amy covered exercise/tax liability with 10,453 shares and converted options into 26,921 shares, increasing direct ownership by 87% to 35,419 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    2/3/26 10:01:46 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Chief Human Resources Officer Gomez Tammy L converted options into 4,342 shares and covered exercise/tax liability with 1,332 shares, increasing direct ownership by 53% to 8,665 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    1/5/26 5:34:29 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Solventum Corporation

    4 - Solventum Corp (0001964738) (Issuer)

    12/3/25 7:22:15 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Solventum Corporation

    SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)

    1/27/26 12:15:19 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    12/16/25 9:02:04 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Solventum Corporation

    SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)

    11/13/25 8:45:09 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Financials

    Live finance-specific insights

    View All

    Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Feb. 26, 2026 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 Internation

    2/3/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Completes Acquisition of Acera Surgical

    Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac

    12/23/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports Third Quarter 2025 Financial Results

    Reported sales increased 0.7%; organic sales increased 2.7%Expects full year organic sales growth to be at the high end of +2.0% to +3.0% rangeIncreases full year adjusted earnings per share outlook to $5.98 to $6.08Announces 4-year 'Transform for the Future' initiativeST. PAUL, Minn., Nov. 6, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales increased 0.7% to $2.1 billion; up 2.7% on an organic basisGAAP diluted earnings per share of $7.22; adjusted diluted earnings p

    11/6/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    View All

    Solventum Appoints Heather Knight as Chief Commercial Officer

    ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale

    10/21/25 5:00:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

    BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

    2/11/25 8:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

    Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

    1/8/25 6:30:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care